Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Raltegravir treatment response in an HIV-2 infected patient: a case report.

Literature DB >> 18520356

Raltegravir treatment response in an HIV-2 infected patient: a case report.

Nigel Garrett, Li Xu, Erasmus Smit, Bridget Ferns, Saleh El-Gadi, Jane Anderson.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2008 PMID： 18520356 DOI： 10.1097/QAD.0b013e3282f9b165

Source DB: PubMed Journal: AIDS ISSN： 0269-9370 Impact factor: 4.177

Keyword Cloud
Cited

× No keyword cloud information.

20 in total

1. Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.

Authors: Charlotte Charpentier; Bénédicte Roquebert; Olivier Delelis; Lucile Larrouy; Sophie Matheron; Roland Tubiana; Marina Karmochkine; Xavier Duval; Geneviève Chêne; Alexandre Storto; Gilles Collin; Antoine Bénard; Florence Damond; Jean-François Mouscadet; Françoise Brun-Vézinet; Diane Descamps
Journal: Antimicrob Agents Chemother Date: 2010-12-28 Impact factor: 5.191

Review 2. Antiretroviral drug resistance in human immunodeficiency virus type 2.

Authors: Michel L Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Ricardo J Camacho; Mark A Wainberg
Journal: Antimicrob Agents Chemother Date: 2009-05-26 Impact factor: 5.191

3. HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen?

Authors: Daniela Francisci; Laura Martinelli; Liliana E Weimer; Maurizio Zazzi; Marco Floridia; Giulia Masini; Franco Baldelli
Journal: Clin Drug Investig Date: 2011 Impact factor: 2.859

4. The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.

Authors: Robert A Smith; Dana N Raugi; Vincent H Wu; Sally S Leong; Kate M Parker; Mariah K Oakes; Papa Salif Sow; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal: Antimicrob Agents Chemother Date: 2015-09-21 Impact factor: 5.191

5. A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa.

Authors: Selly Ba; Dana N Raugi; Robert A Smith; Fatima Sall; Khadim Faye; Stephen E Hawes; Papa Salif Sow; Moussa Seydi; Geoffrey S Gottlieb
Journal: Clin Infect Dis Date: 2018-10-30 Impact factor: 9.079

Raltegravir treatment response in an HIV-2 infected patient: a case report.

1. Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.

Review 2. Antiretroviral drug resistance in human immunodeficiency virus type 2.

3. HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen?

4. The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.

5. A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa.

6. Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.

7. Optimal use of raltegravir (Isentress(R)) in the treatment of HIV-infected adults - Canadian consensus guidelines.

8. Raltegravir: The evidence of its therapeutic value in HIV-1 infection.

Review 9. Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients.

10. In Vitro Antiviral Activity of Cabotegravir against HIV-2.